<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929797</url>
  </required_header>
  <id_info>
    <org_study_id>CD8+NKG2D+ AKT</org_study_id>
    <nct_id>NCT02929797</nct_id>
  </id_info>
  <brief_title>Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer</brief_title>
  <acronym>AKT</acronym>
  <official_title>A Randomized, Double Blinding, Placebo-Controlled Clinical Trials of CD8+NKG2D+ AKT Cell Immunotherapy to the Pancreatic Cancer Patients Treated With Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the
      pancreatic cancer patients treated with adjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune indices</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>AKT + gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine dose 1000mg/M^2, d1,8,15，q4w ×6 AKT 5*10^8/M^2, d16,q4w ×6 Drug: gemcitabine Biological: AKT, CD8+NKG2D+ AKT Cell</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gemcitabine hydrochloride dose 1000mg/M2 d1,8,15，q4w ×6 Drug: gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD8+NKG2D+ AKT Cell</intervention_name>
    <description>AKT: CD8+NKG2D+ AKT cell</description>
    <arm_group_label>AKT + gemcitabine</arm_group_label>
    <other_name>AKT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>gemcitabine</description>
    <arm_group_label>AKT + gemcitabine</arm_group_label>
    <arm_group_label>gemcitabine</arm_group_label>
    <other_name>GEM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Diagnosed as stage II-III pancreatic ductal adenocarcinoma patients by pathologic
             histology;

          -  2. Pancreatic cancer after radical resection;

          -  3. Eastern Cooperative Oncology Group Performance Status less than 2;

          -  4. Without radiotherapy or neoadjuvant chemotherapy;

          -  5. The man or the gestation and lactation women Age between 18 to 80 years old;

          -  6. Bone marrow functioned well: ANC more than 1.5*10^9/ L, PLT more than 100*10^9/LHgb
             more than 9 g/dL;

          -  7. Blood biochemical indicators: AST（SGOT）less than 1.5 ULNALT（SGPT）less than 1.5 ULN,
             TBIL less than 1.5 ULN;

          -  8. PT and PPT are in normal ranges;

          -  9. Three months prior to clinical research did not receive any other clinical research
             trials;

          -  10. patients are voluntary, and willing to sign informed consent.

        Exclusion Criteria:

          -  1. Patients with other malignant tumors in the past five years;

          -  2. Active viral or bacterial infection and cannot be controlled with appropriate
             anti-infection treatment;

          -  3. Known as HIV infection, active hepatitis B virus or hepatitis C virus infection;

          -  4. Known allergy to any kind of component of study drugs;

          -  5. History of connective tissue disease(Such as lupus, scleroderma, nodular
             arteritis);

          -  6. Patients with a history of interstitial pneumoniaSlowly progressive difficulty in
             breathing and hoose Sarcoidosissilicosis Fibrose pulmonaire idiopathiquehylactic
             pneumonia or A variety of allergy;

          -  7. Suffering from mental illness or other illness, such as heart or lung disease,
             diabetes, etc. that can not be controlled, and can not cope with study treatment and
             monitoring requirements;

          -  8. At the same time Patients participate in any other use of interventional medicine
             clinical research or checkers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hongxia Wang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hongxia Wang, Dr.</last_name>
    <phone>8621-63240090</phone>
    <email>whx365@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201620</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shupeng Guo, Dr</last_name>
      <phone>18817943845</phone>
      <email>gsp88@foxmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>201620</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shupeng Guo, Dr</last_name>
      <phone>18817943845</phone>
      <email>gsp88@foxmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hongxia Wang</investigator_full_name>
    <investigator_title>Deputy Director of Oncology</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

